SCHEMBL275404

SCHEMBL275404

CC(C)(C)OC(=O)N1CCC(Oc2ccc(C(F)(F)F)cc2C=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.52
PDE4D Q08499 3/20 0.50
PDE4B Q07343 3/20 0.50
PDE4A P27815 2/20 0.50
PDE4C Q08493 2/20 0.50
STS P08842 1/20 0.46
KDM1A O60341 1/20 0.45
MAPT P10636 1/20 0.44
P2RY14 Q15391 1/20 0.44
TOP2A P11388 1/20 0.43
TGFBR1 P36897 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28532412 0.87 GPR119 (0.55) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL2420719 0.85 PDE4B (0.52) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL22462754 0.85 GPR119 (0.58) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL20569833 0.85 GPR119 (0.53) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL275205 0.85 PDE4B (0.52) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL18609604 0.85 GPR119 (0.53) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL274655 0.85 PDE4B (0.52) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL29716374 0.83 GPR119 (0.56) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL3157462 0.83 PDE4B (0.49) GPR119PDE4DPDE4BPDE4APDE4C
SCHEMBL279069 0.82 GPR119 (0.44) GPR119PDE4DPDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT GPR119 2589/4885PDE4D 2759/4885PDE4B 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.